Drug intelligence / Profile preview

n6-cyclopentyladenosine

Development stage
Preclinical
Modality
Small Molecules
Administration
Experimental; Commonly Intramuscular, Intravenous, Intraperitoneal, Or Similar Routes In Animal/laboratory Models
01

Overview

N6-cyclopentyladenosine is a **selective adenosine A1 receptor agonist** used primarily as a pharmacological tool in scientific research. It displays high affinity for the adenosine A1 receptor (Ki = 2.3 nM), with much lower affinity for A2A (Ki = 790 nM) and A3 (Ki = 43 nM) receptors, and very low activity at A2B (EC50 = 18600 nM)[1][16]. Its main effects are **cardiovascular—bradycardia and hypotension—via adenosine A1 receptor activation**; it also produces behavioral and central nervous effects, such as memory impairment and modulation of seizure thresholds in animal models[3][7][12]. It is **not approved for clinical or therapeutic use**, but widely used as a reference agonist for adenosine A1 receptor function in cardiovascular, neurological, and biochemical studies.

Other names
cyclopentyladenosineN-cyclopentyladenosineN(6)-cyclopentyladenosineadenosine N-cyclopentyl-N(sup 6)-cyclopentyladenosine
02

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on n6-cyclopentyladenosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n6-cyclopentyladenosine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call